Angiotensin II receptor blocker (ARB): Class Overview and Comparison
Quick answer: Angiotensin II receptor blocker (ARB) are a class of medicines used for specific therapeutic indications. iMedic covers 10 angiotensin ii receptor blocker (arb) substances. Below is a comparison table linking to detailed pages for each.
Angiotensin II receptor blocker (ARB) on iMedic (10 substances)
| Substance | Primary indications | Mechanism | Common dose |
|---|---|---|---|
| Aprovel | Hypertension, Diabetic nephropathy | Selective angiotensin II type 1 receptor antagonist causing vasodilation | 150-300 mg once daily |
| Candesartan | Hypertension, Heart failure | Selective AT1 receptor antagonist blocking angiotensin II vasoconstrictor and al | 8-32 mg once daily |
| Edarbi | Hypertension | Selective angiotensin II type 1 (AT1) receptor antagonist that lowers blood pres | 40-80 mg once daily |
| Irbesartan | Hypertension, Diabetic nephropathy | Selective angiotensin II type 1 (AT1) receptor antagonist causing vasodilation a | 150-300 mg once daily |
| Kinzalmono | Hypertension, Cardiovascular risk reduction | Telmisartan selectively blocks the AT1 angiotensin II receptor, lowering blood p | 40-80 mg once daily |
| Losartan | Hypertension, Diabetic nephropathy | Selectively blocks the angiotensin II type 1 (AT1) receptor causing vasodilation | 25-100 mg once daily |
| Micardis | Hypertension, Cardiovascular risk reduction | Telmisartan selectively blocks the AT1 receptor, reducing vasoconstriction and a | 40-80 mg once daily |
| Pritor | Hypertension, Cardiovascular risk reduction | Selective angiotensin II type 1 (AT1) receptor antagonist; brand name for telmis | 40-80 mg once daily |
| Telmisartan | Hypertension, Cardiovascular risk reduction | Selectively blocks angiotensin II AT1 receptors causing vasodilation and reduced | 20-80 mg once daily |
| Valsartan | Hypertension, Heart failure | Selectively blocks the AT1 angiotensin II receptor, causing vasodilation and red | 80-320 mg once daily |
About Angiotensin II receptor blocker (ARB)
Angiotensin II receptor blocker (ARB) share a common mechanism of action and clinical use. Specific dosing, side effects, contraindications, and drug interactions vary between individual substances within the class. Click any substance above for full prescribing information and patient guidance.
Common considerations across the class
- Indication-specific selection: Different members may be preferred for different conditions or patient populations
- Dose equivalence: Members of the same class are not always interchangeable on a 1:1 dose basis
- Drug interactions: Class members often share interaction profiles (e.g., CYP enzyme effects) but individual variation matters
- Side effects: Some side effects are class-wide; others are substance-specific
- Contraindications: Individual contraindications may not generalize across the class
Always consult the prescribing information for the specific medicine prescribed and discuss with your clinician.
Frequently asked questions
What are Angiotensin II receptor blocker (ARB)?
Angiotensin II receptor blocker (ARB) are medicines that share a common mechanism of action used for specific therapeutic indications. iMedic currently covers 10 substances in this class with detailed pages for each.
Are all Angiotensin II receptor blocker (ARB) interchangeable?
No. While medicines in the same class share a mechanism, they differ in potency, dosing, drug interactions, and tolerability. Switching between them is a clinical decision based on individual response, side effects, and treatment goals.
How do I choose between different Angiotensin II receptor blocker (ARB)?
Selection depends on the specific clinical indication, patient factors (age, comorbidities, kidney/liver function, other medications), tolerability of side effects, cost, and clinician preference. This is a prescribing decision.
Are Angiotensin II receptor blocker (ARB) available as generics?
Most well-established class members are available as generic alternatives, often substantially less expensive than brand-name versions while clinically equivalent. Newer members may still be brand-only.
Last reviewed: by iMedic Medical Editorial Team. Our editorial process.